Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Two-arm, Prospective, Observational Study to Characterize the Tolerability of Treatment With Enzalutamide or Abiraterone Acetate (With Prednisone) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT02663193 is registered in ClinicalTrials.gov with Janssen Scientific Affairs, LLC as lead sponsor.

NCT NCT02663193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02663193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Two-arm, Prospective, Observational Study to Characterize the Tolerability of Treatment With Enzalutamide or Abiraterone Acetate (With Prednisone) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Janssen Scientific Affairs, LLC
Phase
Observational
Overall status
Completed
Start date
December 31, 2015
Completion date
January 31, 2017
Enrollment
108 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer